$(2)$

PROF. JAMAL AL WAKEEL
consultant Nephrology Dívision Department of Medicine


## The Objectives of this Lecture are:

1. To be able to recognize the definition of hypertension
2. To be able to identify the Stages of Hypertension ( ACCIAHA European Society of Cardiology/European Society of Hypertension (ESC/ESH)
3. To find out the complication of Hypertension
4. To learn how to measure blood pressure
5. To acquire knowledge on how to treat hypertension

## Case

47 year old man came to your clinic with headache for 3 weeks. The nurse measure his Blood Pressure and was found to be $150 / 95 \mathrm{mmHg}$ :

1. Does he have Hypertension?
2. What is the stage of Hypertension?
3. What investigation should you perform?
4. What could be your management on his case?
5. Is their any possible prevention to his disease and its complication?

## Prevalence of hypertension

- The $4^{\text {th }}$ most common cause of death worldwide
- The overall prevalence of hypertension in adults is around 30-45\%
- The global prevalence of hypertension was estimated to be 1.13 billion in 2015
- Onset stage 25-55 years mainly in 40-50y
- more common with advancing age
- prevalence of $>60 \%$ in people aged $>60$ years
- Risk of HTN : A)As populations age, B) sedentary lifestyles $C$ ) increase their body weight


## * Only 72\% are aware of their disease

* The overall prevalence of hypertension in Saudia was $\mathbf{2 5 . 5 \%}$
$55 \%$ of participants on medication for hypertension had their blood pressure uncontrolled


## Mechanism of Blood Pressure:

Blood Pressure $=$ Cardiac output $\quad X$
Systemic Vascular Resistance
= CO X SVR
= Stroke volume X HR X SVR


Figure 1: Systerns involvedin the development and maintenance of hypertension


- Heart rate
- Myocardial


Sympathetic Nervouse System

- Sympathetic tone


Systemic Epinephrine, Systemic Norepinephrine Aldosterone
contractility


Renal Effects
RAAS activation

- Renin Release
- Sodium Retention
- Water Retention
- Systemic

Vasoconstriction

Endothelium
$\rightarrow$ Endothelin-1
$\rightarrow$ Nitric Oxide

Figure 1: Systems involved in the development and maintenance of hypertension


## Hypertension

* In 90\%-95\% of cases no cause can be found primary hypertension (essential)
* Secondary hypertension 5-10\%


## Essential HTN

$\square$ Risk factors (modeflied)
x Obesity---metabolic syndrome
x UnhealthydietExcessive intake
x Excessive alcohol intake
x Polycythemia
$\times$ Lack of exercise

* Non-steroid anti-inflammatory drugs
$\square$ Risk factors (Non modeflied)
x Family history of essential HTN
$\times$ Aging
$\times$ Race \&gentic
$\square$ Caffeine and smoking increase the BP acutely but are not risk factors for the development of chronic essential HTN


## Secondary Hypertension

* Primary renal disease
* Oral contraceptives
* Sleep apnea syndrome
* Primary hyperaldosteronism
* Renovascular disease
+ Cushing's syndrome
* Pheochromocytoma
* Other endocrine disorders
+ Coarctation of the aorta


## Types Of BP Apparatuses



Digitital Type

device


- Finger and/or wrist BP measuring devices are not recommended
- AOBP is the preferred method of performing inoffice BP measurement


## Type of Instrument of Blood Pressure Measurement



Home Blood Pressure Monitoring


## Ambulatory Pressure Monitoring



Automated Blood Pressure Tru Device (Automated Office Blood pressure)

Automated
BpTRUTM BP Devices



AOBP $\geq 135 \mathrm{~A} 130$ or more than $85 \overline{\mathrm{~A} \beta 0}$

## Blood Pressure

* Apply to adults on no antihypertensive medications and who are not acutely ill.
* If there is a disparity in category between the systolic and diastolic pressures, the higher value determines the severity of the hypertension.
* Measure blood pressure to arm the high reading.


## Office blood pressure measurement

* To allow the patients to sit for 3-5 minutes before beginning BP measurements
* Back straight and arm supported at heart level
* Take at least two BP measurements, spaced $1-2$ min apart, and additional measurements if the first two are quite different.
* Consider the average BP if deemed appropriate.
+ To use a standard bladder (12-13 cm wide and 35 cm long)
* A larger bladder for larger arm (circumference >32 cm)
* The bladder of the pressure cuff should encircle at least $80 \%$ of the upper arm



## Office blood pressure measurement

* Place the cuff at the heart level, whatever the position of the patient.
* Measure BP in both arms at first visit to detect possible differences. In this instance, take the arm with the higher value as the reference.
* Measure BP in sitting and standing position in elderly subjects and diabetic patients
* Use phase I and V (disappearance) Korotkoff sounds to identify systolic and diastolic BP, respectively.


## Korotkoff sounds

| Phase | Korotkoff sounds | 120 mmHg systolic |
| :---: | :---: | :---: |
|  |  |  |
| I | A thud |  |
| II | A blowing noise |  |
| III | A soffer thud |  |
| IV | A disappearing blowing noise |  |
| V | Nothing |  |


*The diagnosis of mild hypertension should not be made until the blood pressure has been measured on at least two time in three visits within1-3 months
+Average of 10 to 15 mmHg decrease between visits 1 and three
\$The diagnosis of sever asympotomatic hypertension (>160/110) should be made until the blood pressure has been measured on at least two time in two visits one or 2 week apart

## White Coat Hypertension(PseudoHTN)

\& a phenomenon in which patients exhibit a blood pressure level above the normal range, in a clinical setting, though they do not exhibit it in other settings
\& Approximately 20 to $25 \%$ of patients with mild office hypertension
\& More common in elderly
\& Infrequent in patients with office diastolic pressures $\geq 105 \mathrm{mmHg}$

## Masked hypertension

office blood pressure (BP) level is $<140 / 90 \mathrm{~mm}$ Hg but ambulatory or home BP readings are in the hypertensive range

- In adults with untreated office BPs that are consistently between 120 mm Hg and 129 mm Hg for SBP or between 75 mm Hg and 79 mm Hg for DBP, screening for masked hypertension with home BPM (or ABPM) is reasonable.

The prevalence about 1 in 7 or 8 persons

## Cardiology/European Society of Hypertension (ESC/ESH)

Table 3 Classification of office blood pressure ${ }^{a}$ and definitions of hypertension grade ${ }^{b}$

| Category | Systolic (mmHg) |  | Diastolic (mmHg) |
| :--- | :---: | :---: | :---: |
| Optimal | $<120$ | and | $<80$ |
| Normal | $120-129$ | and/or | $80-84$ |
| High normal | $130-139$ | and/or | $85-89$ |
| Grade 1 hypertension | $140-159$ | and/or | $90-99$ |
| Grade 2 hypertension | $160-179$ | and/or | $100-109$ |
| Grade 3 hypertension | $\geq 180$ | and/or | $\geq 110$ |
| Isolated systolic hypertension ${ }^{\text {b }}$ | $\geq 140$ | and | $<90$ |

[^0]
## Categories of BP in Adults*

| BP Category | SBP |  | DBP |
| :--- | :---: | :---: | :---: |
| Normal | $<120 \mathrm{~mm} \mathrm{Hg}$ | and | $<80 \mathrm{~mm} \mathrm{Hg}$ |
| Elevated | $120-129 \mathrm{~mm}$ <br> Hg | and | $<80 \mathrm{~mm} \mathrm{Hg}$ |
| Hypertension |  |  |  |
| Stage 1 | $130-139 \mathrm{~mm}$ <br> Hg | or | $80-89 \mathrm{~mm}$ <br> Hg |
| Stage 2 | $\geq 140 \mathrm{~mm} \mathrm{Hg}$ | or | $\geq 90 \mathrm{~mm} \mathrm{Hg}$ |

*Individuals with SBP and DBP in 2 categories should be designated to the higher BP category.
BP indicates blood pressure (based on an average of $\geq 2$ careful readings obtained on $\geq 2$ occasions, as detailed in DBP, diastolic blood pressure; and SBP systolic blood pressure.

## European Society of Nephrology Classification of Blood Pressure Levels

| Category | Systolic blood <br> pressure <br> (mmHg) | Diastolic blood <br> pressure (mmHg) |
| :---: | :---: | :---: |
| Optimal blood <br> pressure | $<120$ | $<80$ |
| Normal blood <br> pressure | $<130$ | $<85$ |
| High-normal blood <br> pressure | $130-139$ | $\mathbf{8 5 - 8 9}$ |
| Grade 1 <br> hypertension (mild) | $\mathbf{1 4 0 - 1 5 9}$ | $\mathbf{9 0 - 9 9}$ |
| Grade 2 <br> hypertension <br> (moderate) | $160-179$ | $100-109$ |
| Grade 3 <br> hypertension <br> (severe) | $>/=180$ | $>/=110$ |
| Isolated systolic <br> hypertension | $>140$ | $<90$ |

Categories of BP in Adults* ${ }^{*}$

| BP Category | SBP |  | DBP |
| :--- | :---: | :---: | :---: |
| Normal | $<120 \mathrm{~mm} \mathrm{Hg}$ | and | $<80 \mathrm{~mm} \mathrm{Hg}$ |
| Elevated | $120-129 \mathrm{~mm}$ <br> Hg | and | $<80 \mathrm{~mm} \mathrm{Hg}$ |
| Hypertension |  |  |  |
| Stage 1 | $130-139 \mathrm{~mm}$ <br> Hg | or | $80-89 \mathrm{~mm}$ <br> Hg |
| Stage 2 | $\geq 140 \mathrm{~mm} \mathrm{Hg}$ | or | $\geq 90 \mathrm{~mm} \mathrm{Hg}$ |

*Individuals with SBP and DBP in 2 categories should be designated to the higher BP category. $B P$ indicates blood pressure (based on an average of $\geq 2$ careful readings obtained on $\geq 2$ occasions, as detailed in DBP, diastolic blood pressure; and SBP systolic blood pressure.

## Definitions of hypertension by office and out-of-office blood pressure levels

| Category | Systolic BP (mmHg) |  | Diastolic (mmHg) |
| :--- | :--- | :--- | :--- |
| Office BP | $\geq 140 \mathrm{Al30} /$ | and/or | $\geq 90$ A80 |
| Ambulatory BP |  |  |  |
| Daytime (or awake) | $\geq 135 \mathrm{Al30}$ | and/or | $\geq 85 \mathrm{~A} 80$ |
| Nighttime (or sleep) | $\geq 120 \mathrm{Al10}$ | and/or | $\geq 70 \mathrm{~A} 65$ |
| 24 h | $\geq 130 \mathrm{Al25}$ | and/or | $\geq 80 \mathrm{~A} 75$ |
| Home BP | $\geq 135 \mathrm{Al30}$ | and/or | $\geq 85 \mathrm{~A} 80$ |

## Essential arterial hypertension




This left ventricle is very thickened (slightly over 2 cm in thickness), but the rest of the heart is not greatly enlarged. This is typical for hypertensive heart disease. The hypertension creates a greater pressure load on the heart to induce the hypertrophy.


The left ventricle is markedly thickened in this patient with severe hypertension that was untreated for many years. The myocardial fibers have undergone hypertrophy.

## COMPLICATIONS



Stroke, Ischemia,
Hemorrhage, Alzheimer's Disease, Cognitive, retinal hemorrhage


Hypertension

## Hypertensive Emergency

Severe hypertension (diastolic blood pressure above 120 mmHg ) in end organ damage (MI,STROKE,AKI,CHF)

## Hypertensive Urgency

+ Severe hypertension (diastolic blood pressure above 120 mmHg ) in asymptomatic patients
* There is no proven benefit from rapid reduction in BP in asymptomatic patients who have no evidence of acute end-organ and are little short-term risk


## Malignant (Accelerated) Hypertension

* Marked hypertension with encephapapathy\& retinal hemorrhages, exudates, or papilledema
* Associated with a diastolic pressure above 120 mmHg


## HYPERTENSIVE RETINOPATHY

| Grade | Description |
| :---: | :--- |
| I | Minimal narrowing of retinal arteries |
| II | Narrowing of retinal arteries in conjunction with <br> regions of focal narrowing and arterio-venous <br> nipping |
| III | Abnormalities seen in Grade I and II, as well as retinal <br> hemorrhages, hard exudation and cotton wool spots. |
| IV | Abnormalities encountered in Grades I through III, as <br> well as swelling of the optic nerve head and macular <br> star |

## Hypertensive Retinopathy Grade 1

Generalized arteriolar constrictio n-seen as

silver

wiring ${ }^{\prime}$
and
Vascular tortuosities

Narrowing of retinal arteries in conjunction with regions of focal narrowing and arterio-venous nipping

## Copper wirting



## Hypertensive Retinopathy Grade 2

 Arteriovenous nicking in association with hypertension Grade 2(yellow arrow)


## Hypertensive Retinopathy Grade 3

## Flame-shaped hemorrhage in association with severe hypertension Grade 3 (yellow arrow)



## Hypertensive Retinopathy Grade

4
Papilledema malignant hypertension. There is blurring of the borders of the optic disk with hemorrhages (yellow arrows) and exudates (white arrow)


## Diagnosis Hypertension

Clinical Presentations:
\& Asymptomatic

* Headache
+ Epistaxis
+ Chest discomfort
+ Symptom of complications

Screening:
\& Every one years for persons with systolic and diastolic pressures below 120 mmHg and 80 mmHg

## Physical Examination

1. Confirm the diagnosis of hypertension
2. Detect causes of secondary hypertension
3. Assess CV risk
4. Organ damage
5. Concomitant clinical conditions.

| Important aspects of the physical examination in the hypertensive patient |
| :--- |
| Accurate measurement of blood pressure |
| General appearance |
| Distribution of body fat |
| Skin lesions |
| Muscle strength |
| Alertness |
| Fundoscopy |
| Hemorrhage |
| Papilledema |
| Cotton-wool spots |
| Neck |
| Palpation and auscultation of carotids |
| Thyroid |
| Heart |
| Size |
| Rhythm |
| Sounds |
| Lungs |
| Rhonchi |
| Rales |
| Abdomen |
| Renal masses |
| Bruits over aorta or renal arteries |
| Femoral pulses |
| Extremities |
| Peripheral pulses |
| Edema |
| Neurologic assessment |
| Visual disturbance |
| Focal weakness |
| Confusion |

## Laboratory Tests

\& Routine Tests
$\times$ Electrocardiogram
$\times$ Urinalysis
$\times$ Serum sodium, serum potassium, creatinine, or the corresponding estimated GFR, and calcium $\times$ Blood glucose, and hematocrit
$\times$ Lipid profile, after 9 - to 12 -hour fast, that includes high density and low-density lipoprotein cholesterol, and triglycerides
\& Optional tests
$\times$ Measurement of urinary albumin excretion or albumin/creatinine ratio

* More extensive testing for identifiable causes is not generally indicated unless BP control is not achieved


# RECOMMENDATIONS FOR TREATMENT 5 

Normal BP
( $<120 / 80$ )

Promote optimal lifestyle habits

Reassess in 1 year

Elevated BP
(120-129/<80)

Nonpharmacologic
therapies

Reassess in 3-6 months

# RECOMMENDATIONS FOR TREATMENT 

Stage 1 Hypertension
(130-139/80-89)

Nonpharmacologic
Therapy

No Clinical ASCVD or 10 yr CVD risk $\geq 10 \%$

Stage 2 Hypertension $(\geq 140 / 90)$

Nonpharmacologic Therapy and Medication

Reassess in 3-6 months
Atherosclerotic Cardiovasular Disease Calculator

First line initial antihypertensive drugs include ACE, ARB, CCB, or thiazide diuretic

Heart Risk Calculator

| Age (years) | 40-79 |
| :---: | :---: |
| Gender | - Male |
|  | - Female |
| Race | African American |
|  | - Other |
| Total cholesterol (mg/dL) | 130-320 |
| HDL cholesterol (mg/dL) | 20-100 |
| Systolic blood pressure ( mmHg ) | 90-200 |
| Diastolic blood pressure ( mmHg ) | 30-140 |
| Treated for high blood pressure | - No |
|  | - Yes |
| Diabetes | - No |
|  | - Yes |
| Smoker | - No |
|  | Yes |
|  | Calculate |

## Blood Pressure (BP) Thresholds and Recommendations for Treatment and Follow-Up



## Targated BP

BP Thresholds for and Goals of Pharmacological Therapy in Patients With Hypertension According to Clinical Conditions

| Clinical Condition(s) | BP <br> Threshold, <br> mm Hg | BP Goal, <br> mm Hg |
| :--- | :--- | :--- |
| General | $\geq 130 / 80$ | $<130 / 80$ |
| Clinical CVD or 10-year ASCVD risk $\geq 10 \%$ | $\geq 140 / 90$ | $<130 / 80$ |
| No clinical CVD and 10-year ASCVD risk $\mathbf{< 1 0 \%}$ | $\geq 130$ (SBP) | $<130$ (SBP) |
| Older persons ( $\geq 65$ years of age; noninstitutionalized, <br> ambulatory, community-living adults) |  |  |
| Specific comorbidities | $\geq 130 / 80$ | $<130 / 80$ |
| Diabetes mellitus | $\geq 130 / 80$ | $<130 / 80$ |
| Chronic kidney disease | $\geq 130 / 80$ | $<130 / 80$ |
| Chronic kidney disease after renal transplantation | $\geq 130 / 80$ | $<130 / 80$ |
| Heart failure | $\geq 130 / 80$ | $<130 / 80$ |
| Stable ischemic heart disease | $\geq 140 / 90$ | $<130 / 80$ |
| Secondary stroke prevention | $\geq 130 / 80$ | $<130 / 80$ |
| Secondary stroke prevention (lacunar) | $\geq 130 / 80$ | $<130 / 80$ |
| Peripheral arterial disease |  |  |

ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; CVD, cardiovascular disease; and SBP, systolic blood pressure.

## Follow-Up After Initial BP Evaluation (cont.)

## Recommendation for Follow-Up After Initial BP Elevation

For adults with a very high average BP (e.g., SBP> 180 mm Hg or DBP > 110 mm Hg ), evaluation followed by prompt antihypertensive drug treatment is recommended.

For adults with a normal BP, repeat evaluation every year is reasonable

## Lifestyle changes:

The DASH diet (Dietary Approaches to Stop Hypertension)

* Salt restriction to 5-6 gm/day.
* Increased consumption of vegetables, fruits and low-fat dairy products.
* 7-8 servings/day of grain/grain products, 45 vegetable, 4-5 fruit
+ Reduction of weight to BMI of $25 \mathrm{~kg} / \mathrm{m}^{2}$.
* Regular exercise ( $\geq 30 \mathrm{~min}$ of moderate dynamic exercise on 5-7 days per week)
+ Smoking cessation

Best Proven Nonpharmacological Interventions for Prevention and Treatment of Hypertension*

|  | Nonpharmacologi <br> -cal Intervention | Dose | Approximate Impact on SBP |  |
| :--- | :--- | :--- | :--- | :--- |
|  | Weight/body fat | Best goal is ideal body weight, but aim <br> for at least a 1-kg reduction in body <br> weight for most adults who are <br> overweight. Expect about 1 mm Hg for <br> every 1-kg reduction in bodyweight. | -5 mm Hg | $-2 / 3 \mathrm{~mm} \mathrm{Hg}$ |
| Weight loss | Wormotension |  |  |  |
| Healthy diet | DASH dietary <br> pattern | Consume a diet rich in fruits, <br> vegetables, whole grains, and low-fat <br> dairy products, with reduced content <br> of saturated and total fat. | -11 mm Hg | -3 mm Hg |
| Reduced intake <br> of dietary <br> sodium | Dietary sodium | Optimal goal is <1500 mg/d, but aim <br> for at least a $1000-\mathrm{mg} / \mathrm{d}$ reduction in <br> most adults. | $-5 / 6 \mathrm{~mm} \mathrm{Hg}$ | $-2 / 3 \mathrm{~mm} \mathrm{Hg}$ |
| Enhanced <br> intake of <br> dietary <br> potassium | Dietary <br> potassium | Aim for 3500-5000 mg/d, preferably <br> by consumption of diet rich in <br> potassium. | $-4 / 5 \mathrm{~mm} \mathrm{Hg}$ | -2 mm Hg |

*Type, dose, and expected impact on BP in adults with a normal BP and with hypertension.
DASH indicates Dietary Approaches to Stop Hypertension; and SBP, systolic blood pressure. Resources: Your Guide to Lowering Your Blood Pressure With DASH—How Dol Make the DASH? AMERICAN Available at: https://howw.nhlbi.nih.gov/health/resources/heart/hbp-dash-how-to.

## Best Proven Nonpharmacological Interventions for Prevention and Treatment of Hypertension* (cont.)

|  | Nonpharmacologica I Intervention | Dose | Approximate Impact on SBP |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  |  | Hypertension | Normotension |
| Physical activity | Aerobic | - 90-150 min/wk <br> - $65 \%-75 \%$ heart rate reserve | -5/8 mm Hg | -2/4 mm Hg |
|  | Dynamic resistance | - 90-150 min/wk <br> - $50 \%-80 \% 1$ rep maximum <br> - 6 exercises, 3 sets/exercise, 10 repetitions/set | -4 mm Hg | -2 mm Hg |
|  | Isometric resistance | - $4 \times 2 \mathrm{~min}$ (hand grip), 1 min rest between exercises, $30 \%-40 \%$ maximum voluntary contraction, 3 sessions/wk <br> - 8-10 wk | -5 mm Hg | -4 mm Hg |
| Moderation in alcohol intake | Alcohol consumption | In individuals who drinkalcohol, reduce alcoholt to: <br> - Men: $\leq 2$ drinks daily <br> - Women: $\leq 1$ drink daily | -4 mm Hg | -3 mm |

*Type, dose, and expected impact on BP in adults with a normal BP and with hypertension.
HIn the United States, one "standard" drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of regular beer (usually about $5 \%$ alcohol), 5 oz of wine (usually about $12 \%$
alcohol), and 1.5 oz of distilled spirits (usually about $40 \%$ alcohol)
American
Heart
Association. CARDIOLOGY

## Blood Pressure Reductions as Little as $\underline{\mathbf{2} m m H g}$ Reduce the Risk of

 Cardiovascular Events by up to 10\%

Meta-analysis of 61 prospective, observational studies conducted by Lewington et al involving one million adults with no previous vascular disease at baseline mmHg

${ }^{12}$ Choose a low-cost ARB.
${ }^{13}$ A CCB is preferred but consider $a$ thiazide-like diuretic if a CCB is not tolerated or the person has edema, evidence of heart failure or a high risk of heart failure.
${ }^{14}$ Consider a low dose of spironolactone ${ }^{15}$ or higher doses of a thiazide-like diuretic.
${ }^{15}$ At the time of publication (August 2011), spironolactone did not have a UK marketing authorization for this indication. Informed consent should be obtained and documented.
${ }^{16}$ Consider an alpha- or betablocker iffurther diuretic therapy is not tolerated, or is contraindicated or ineffective.


* Possible combinations of classes of antihypertensive drugs. Green continuous lines: preferred combinations; green dashed line: useful combination (with some limitations); black dashed lines: possible but less well-tested combinations; red continuous line: not recommended combination.
* Although verapamil and dilliazem are sometimes used with a beta-blocker to improve ventricular rate control in permanent atrial fibrillation, only dihydropyridine calcium antagonists should normally be combined with beta-blockers.


## Benefits of Lowering BP

## Average Percent Reduction

| Stroke incidence | $35-40 \%$ |
| :---: | :---: |
| Myocardial <br> infarction | $20-25 \%$ |
| Heart failure | $50 \%$ |
| Renal Failure | $35-50 \%$ |

## Anti-hypertensive Medications and

## Complications

\#Diuretics $\rightarrow$ Hypokalemia
$\notin$-Adrenergic Blocking Agents $\rightarrow$ Bradycardia *Angiotensin-Converting Enzyme Inhibitors $\rightarrow$ Hyperkalemia + cough
*Angiotensin II Receptor Blockers $\rightarrow$ Hyperkalemia $\not$ Calcium Channel Blocking Agents $\rightarrow$ Edema + Tachycardia + Bradycardia
\# $\alpha$-Adrenoceptor Antagonists $\rightarrow 1^{\text {st }}$ dose hypotension
\# Drugs with Central Sympatholytic Action $\rightarrow$ Drowsiness
\#Arteriolar Dilators $\rightarrow$ Tachycardia + Edema

## High Risk Group Therapy

* Start in 130/80(130-139)/(85-89) mmHg Lifestyle change +Medication

BP target of less than $130 / 80 \mathrm{Hg}$ is recommended \& CHF - Thiazide, ACE-1, Aldosterone, BB

* Post Myocardial Infarction - BB, ACEi
\& Diabetes Mellitus - proteinuria ACEi, ARB,NO
$+$
Nonproteinuria Thiazide, CCB,ARB, ACEi
+ CKD - ACEi, ABB, Thiazide
+ Stroke - CCB +ACEi
* Pregnancy Aldomet ,labetalol, Ca channel bloocker


## Targated BP

BP Thresholds for and Goals of Pharmacological Therapy in Patients With Hypertension According to Clinical Conditions

| Clinical Condition(s) | BP <br> Threshold, <br> mm Hg | BP Goal, <br> mm Hg |
| :--- | :--- | :--- |
| General | $\geq 130 / 80$ | $<130 / 80$ |
| Clinical CVD or 10-year ASCVD risk $\geq 10 \%$ | $\geq 140 / 90$ | $<130 / 80$ |
| No clinical CVD and 10-year ASCVD risk $\mathbf{< 1 0 \%}$ | $\geq 130$ (SBP) | $<130$ (SBP) |
| Older persons ( $\geq 65$ years of age; noninstitutionalized, <br> ambulatory, community-living adults) |  |  |
| Specific comorbidities | $\geq 130 / 80$ | $<130 / 80$ |
| Diabetes mellitus | $\geq 130 / 80$ | $<130 / 80$ |
| Chronic kidney disease | $\geq 130 / 80$ | $<130 / 80$ |
| Chronic kidney disease after renal transplantation | $\geq 130 / 80$ | $<130 / 80$ |
| Heart failure | $\geq 130 / 80$ | $<130 / 80$ |
| Stable ischemic heart disease | $\geq 140 / 90$ | $<130 / 80$ |
| Secondary stroke prevention | $\geq 130 / 80$ | $<130 / 80$ |
| Secondary stroke prevention (lacunar) | $\geq 130 / 80$ | $<130 / 80$ |
| Peripheral arterial disease |  |  |

ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; CVD, cardiovascular disease; and SBP, systolic blood pressure.


## summary

The overall prevalence of hypertension in adults is around $30-45 \%$

Lead cause coronary death or myocardial infarction, CHF or fatal or nonfatal stroke,CKD Threshold of treatment start $130 / 80 \mathrm{~mm} \mathrm{Hg}$

- nonpharmacological and antihypertensive drug are effective to reduce all complications in all ages
Thandyou


[^0]:    $B P=$ blood pressure; $S B P=$ systolic blood pressure.
    ${ }^{2} B P$ category is defined according to seated clinic $B P$ and by the highest level of $B P$, whether systolic or diastolic.
    bsolated systolic hypertension is graded 1,2 or 3 according to SBP values in the ranges indicated.
    The same classification is used for all ages from 16 years.

